Navigation Links
BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronie's Disease
Date:10/12/2010

t has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren's contracture; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has gained approval of XIAFLEX in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAFLEX in Europe. More information about the Company may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by BioSpecifics and by its partner Auxilium regarding the ability to obtain regulatory approval of XIAFLEX in the U.S. for Peyronie's disease; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2009 filed with the SEC. There may be additional risks that BioSpecifics does not currently know or that BioSpecifics currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect; therefore, any such factors or forward-looking statements should not be relied upon.
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
11. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2010 Financial Results on May 7, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global Business ... Trust Company (DTC) has made their final decision ... on the Company,s stock effective December 15, 2014, ... stock for depository and book entry transfer services. All ... is now once again fully "DTC Eligible", and ...
(Date:12/17/2014)... Dec. 17, 2014  Beamz Interactive, Inc. (OTCQB: ... products, today announced that it has signed an ... and supplier of innovative prosthetic, orthotic and assistive ... of the agreement, RSL Steeper will promote and ... configured for use within UK residential care facilities ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... SAN DIEGO, June 16, 2011 Neurocrine Biosciences, Inc. ... elagolix presentations have been accepted for the scientific program ... September 4-7, 2011 in Montpellier, France. This important meeting ... every three years, bringing together clinicians and basic scientists ...
... 2011 Cebix Incorporated announced today it ... for the treatment of complications of diabetes. The biopharmaceutical ... evaluate Ersatta™, its proprietary long-acting form of C-peptide, in ... disease, lack this endogenous peptide.  Following the successful completion ...
Cached Medicine Technology:Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 2Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 2Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 4
(Date:12/20/2014)... 20, 2014 Recently, AngelWeddingDress.com has introduced ... ”) for the coming Christmas. In the promotion, all ... off. , “We have something special for the women ... holiday season. Moreover, our new collections of 2015 dresses ... offered now at greatly discounted prices. Visit our website ...
(Date:12/20/2014)... December 20, 2014 Today, Balfleet.com, one ... a Christmas Sale, offering 50%-70% off on its ... season. , The mother of the bride dresses from ... company is 24/7 accessible and takes pride in providing ... , “We are offering great discounts on our mother ...
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 These vanadium ... and other nations. Around 151,000 tons of vanadium were ... The global vanadium usage increased at 6.7% AAGR during ... steel and iron industry, being the largest consumer, accounted ... 2013, followed by titanium-vanadium alloy and the chemical industry. ...
(Date:12/19/2014)... intestinal bacteria that cause inflammatory bowel disease, which includes ... report. The findings, published recently in the journal ... prevent the disease and treat the 1.6 million Americans ... "The intestinal bacteria, or ,gut microbiome, you develop at ... on your health for the rest of your life," ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2
... Lazard CEO Bruce Wasserstein comes under fire as ... care facilities value,private equity gain over safety measures; ... and Wasserstein greed, NEW YORK, July 7 ... launched an online campaign today to,bring attention to ...
... Scientists have identified a new antitumor drug that might ... cancers. The research, published by Cell Press in the ... , advances the understanding of one of the most ... provides new insight into the regulation of the complex ...
... staffing issues and geographic boundaries are some of the ... they plan for a possible influenza pandemic, according to ... health experts who are leading planning efforts for an ... counties, as defined by political lines," said George Avery, ...
... VirtualHealth,Technologies, Inc. (OTC Bulletin Board: VHGI) the ... Prescription Monitoring System announced,it,s support today of ... the electronic,prescribing of controlled substances., June ... would allow physicians to electronically prescribe controlled,substances. ...
... has been found to play a major role in,keeping ... hematopoietic,stem cells, MEMPHIS, Tenn., July 7 The ... run-of-the-mill enzyme that helps to,recycle molecules in cells causes ... St. Jude Children,s Research Hospital investigators., Children with ...
... wine, grape skins, inhibits abnormal cells, study finds , , ... in red grapes and red wine suppresses abnormal cell ... according to U.S. researchers. , The compound, resveratrol, is ... Breast cancer forms through a multi-stage process that differs ...
Cached Medicine News:Health News:Exploitation of Residents at Wasserstein and Lazard-linked Senior Care Facilities Exposed 2Health News:Bacterial peptide provides new insight into common tumor suppressor 2Health News:Political borders, health-care issues complicate pandemic planning 2Health News:Political borders, health-care issues complicate pandemic planning 3Health News:E-prescribing of Controlled Substances Moves Real-Time Prescription Drug Monitoring Toward Reality 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 3Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 4Health News:Dietary Supplement May Prevent Breast Cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: